|
|
|
| Clinical Efficacy of Renshen Yangrong Decoction Combined with Taohong Siwu Decoction in Combination with Conventional Western Medicine in the Treatment of Angina Pectoris after PCI in Patients with Coronary Heart Disease |
| QI Yanwei |
| Department of Cardiology, Liangyuan District Traditional Chinese Medicine Hospital, Shangqiu Henan 476000 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of Renshen Yangrong Decoction combined with Taohong Siwu Decoction in combination with conventional western medicine in the treatment of angina pectoris after percutaneous coronary intervention (PCI) in patients with coronary heart disease. 【Methods】A total of 80 patients with angina pectoris after PCI for coronary heart disease admitted to our hospital from August 2022 to December 2024 were selected and divided into an observation group and a control group according to the random number table method, with 40 cases in each group. The control group received conventional western medicine treatment, and the observation group was given Renshen Yangrong Decoction combined with Taohong Siwu Decoction on the basis of the control group. The efficacy, TCM syndrome scores, myocardial injury markers [creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI), creatine kinase (CK)], and inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP)] were compared between the two groups. 【Results】The total clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the scores of chest pain, dyspnea, palpitations and spontaneous sweating, and fatigue and weakness in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05); the levels of CK-MB, cTnI, CK, IL-6, TNF-α, and hs-CRP in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). 【Conclusion】Renshen Yangrong Decoction combined with Taohong Siwu Decoction in combination with conventional western medicine has a significant clinical efficacy in the treatment of patients with angina pectoris after PCI for coronary heart disease, which can effectively improve myocardial injury and reduce the levels of inflammatory factors.
|
|
Received: 25 March 2025
|
|
|
|
|
|
[1] 周晓萍. PCI与优化药物治疗对老年冠心病患者长期生活质量及预后的影响[J].医学临床研究, 2025,42(3):394-397.
[2] 詹永忠,许贤彬,黄泽伟. 冠心病心绞痛患者PCI围手术期CRP、Lp(a)水平检测及其与心肌损伤的相关性[J].中国医药导报,2021,18(35):76-79.
[3] 王义强,王特,张天时,等. 基于数据挖掘探析中医药治疗冠心病PCI术后心绞痛的证治规律[J].中国老年学杂志,2023,43(4):776-780.
[4] 王阶,孙建宁,何丽云,等.冠心病稳定型心绞痛中医诊疗指南[J].中医杂志,2019,60(21):1880-1890.
[5] 翟梅玲. 冠心病心绞痛患者行PCI术后效果回顾性分析[J].河北医药,2018,40(1):111-113.
[6] LOUIS J V, DEEPAK L B, RICHARD G J, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease[J].Coron Artery Dis,2021,33(2):98-104.
[7] YANG K W, ZHANG L L, LI B, et al. Analysis of acupoint selection and prescription rules of acupuncture for treatment of stable angina pectoris based on a Traditional Chinese Medicine inheritance calculation platform: A systematic review[J].Medicine,2022,101(49):e31466.
[8] 陈红梅,俞鹏,陈晓虎. 中医药治疗经皮冠状动脉介入术后再发心绞痛的研究进展[J].中西医结合心脑血管病杂志,2023,21(17):3179-3183.
[9] 李慧璟,刘雪莹,李兆霖,等. 中医特色疗法治疗冠心病心绞痛的研究进展[J].长春中医药大学学报,2023,39(11):1280-1285.
[10] 别梦迪,曹伟,赖丽娟,等. 中医药治疗冠心病介入术后心绞痛的研究进展[J].大众科技,2023,25(3):167-170.
[11] 王晓杰,杨科.人参养荣汤合桃红四物汤治疗冠心病心绞痛(瘀阻脉络型)的疗效及对血清Asprosin、NT-proBNP和Hcy的影响[J].四川中医, 2021, 39(11):72-74.
[12] 李茉. PCI术后心绞痛采用四参护心汤的临床研究[J].智慧健康,2019,5(30):167-168.
[13] 王晓艳,赵琦,杨建忠.人参养荣汤合桃红四物汤治疗冠心病心绞痛(瘀阻脉络证)的效果及对ET-1、sTM水平的影响[J].临床医学研究与实践,2024,32(9):155-158.
[14] 罗晓梅,吴玉珠,黄培渝,等. 丹参注射液抑制炎症和氧化应激水平保护脓毒症大鼠免受心肌损伤[J].免疫学杂志,2020,36(7):585-591.
[15] 郭施勉,楚英杰. 人参皂苷Rg1对冠心病大鼠心肌细胞凋亡的影响及机制研究[J].中西医结合心脑血管病杂志,2021,19(23):4054-4059. |
|
|
|
2025, Vol. 42 
